Representatives Langworthy and Schrier introduced H.R. 9661 to accelerate biosimilar approvals by reducing clinical trial requirements, following the Senate's advancement of similar legislation (S. 1414) aimed at lowering costs and increasing market access.
Analysis generated by AI. Always verify with official sources.